Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth

24 Jun 2014

Abstract excerpt

PURPOSE: Ewing sarcoma is a pediatric bone tumor that absolutely relies on the transcriptional activity of the EWS/ETS family of fusion oncoproteins. While the most common fusion, EWS/FLI, utilizes lysine-specific demethylase 1 (LSD1) to repress critical tumor suppressors, small-molecule blockade of LSD1 has not yet been thoroughly explored as a therapeutic approach for Ewing sarcoma. We therefore evaluated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24963049
DOI: 10.1158/1078-0432.ccr-14-0072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor GrowthPMID 24963049Read ↗

Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targetingSemantic proximity Read ↗

cIAP1 inhibitor of apoptosis is a tumor suppressor in Ewing sarcomaSemantic proximity Read ↗

LSD1 Performs Demethylase-Independent and Context-Specific Roles in Ewing SarcomaSemantic proximity Read ↗

Mitochondrial Dysfunction is a Driver for SP-2509 Drug Resistance in Ewing SarcomaSemantic proximity Read ↗

Ewing sarcoma fusion oncogene: At the crossroads of transcription and DNA damage responseSemantic proximity Read ↗

Seclidemstat blocks the transcriptional function of multiple FET-fusion oncoproteinsSemantic proximity Read ↗

Epigenetic and Transcriptional Signaling in Ewing Sarcoma—Disease Etiology and Therapeutic OpportunitiesSemantic proximity Read ↗

Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcomaSemantic proximity Read ↗

Oncofusion-driven <i>de novo</i> enhancer assembly promotes malignancy in Ewing sarcoma <i>via</i> aberrant expression of the stereociliary protein LOXHD1Semantic proximity Read ↗

Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1Semantic proximity Read ↗

SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing SarcomaSemantic proximity Read ↗

Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.